This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential.
I participated in 2004 in the creation of the Bioméditerranée cluster foreshadowing the Eurobiomed competitiveness cluster, which is currently the catalyst of the health sector in the Provence-Alpes-Côte d’Azur and Languedoc-Roussillon regions with 400 companies, 8 Universities, 400 research centres, 4 University Hospitals Centres and one Interregional Clinical Research Organization.
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential. Marseille Immunopole is a perfect illustration of this approach and we are very proud of the magnitude taken today by this new operation initiated in 2013. Eurobiomed still remains very involved, animating the community and participating in the driving force that allows the creation of start-ups and the development of industrials and service companies in MI and the implementation of ambitious partnerships in France and internationally on these issues.#ecosystème
Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.
AMU, IPC, CRCM
We and our patients are resolutely committed to the Marseille Immunopôle; patients no longer wish to be simple "providers of biological samples", but full participants in the research process.
MI should enable us to accelerate discovery, enhance our treatment options and offer more innovative options to our patients through current clinical trials and those of the future.
Understanding its mechanisms of action and proposing new diagnostic and therapeutic solutions is the ambitious project that we set with my team.